Form D · Biotechnology

Gemelli Biotech Corp.

Raleigh, NC · CIK 0001780605

Offering snapshot reported Dec 2, 2024 · SEC filing

Reported sold: $21.2M
Investors reported: 128
Minimum accepted: $0
First sale: Dec 7, 2021

Fundraising history

Reported sold

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

Reported sold$18,910,941 → $21,176,893
Reported investors121 → 128

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Dec 2, 2024	Amendment	$21,176,893	$2,265,952vs Jun 8, 2022	128	SEC filing
Jun 8, 2022	Initial	$18,910,941	No comparison	121	SEC filing
Mar 29, 2021	Amendment	$5,500,000	$500,000vs Mar 26, 2021	85	SEC filing
Mar 26, 2021	Initial	$5,000,000	No comparison	85	SEC filing
Jun 28, 2019	Initial	$1,854,978	No comparison	13	SEC filing

Offering details

Securities: Equity
Exemptions: 06b
Duration over one year: Yes
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-448519

Total amount sold includes $5,886,630.10 of cancellation of indebtedness and $15,290,262.98 of new cash.

Source: Form D, filed Dec 2, 2024. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Ritish Agarwal	Director
James Laur	Director
Oded Levy	Director
Matthew Mitcho	Director, Executive
John A. Neczesny	Director
Mark Pimentel	Director, Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:

2009 Fairview Rd. #6099
Raleigh, NC, 27628